common.study.topics.clinical

Ampligen in Chronic Fatigue Syndrome

common.study.values.description

Ampligen in Chronic Fatigue Syndrome

This is an open label study of Ampligen in patients with chronic fatigue syndrome.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Poly I: Poly C12U (Rintatolimod)

200-400 mg IV infusions given twice weekly over a period of 30-60 minutes

participant.views.study.view.additional

participant.views.study.view.scientific-title

An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN®) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)

common.study.values.clinical-trial-id

NCT00215813

participant.views.study.view.id

Pe9xdL